Equities research analysts expect Medidata Solutions Inc (NASDAQ:MDSO) to announce earnings of $0.38 per share for the current quarter, according to Zacks Investment Research. Seven analysts have made estimates for Medidata Solutions’ earnings. The lowest EPS estimate is $0.32 and the highest is $0.46. Medidata Solutions posted earnings of $0.41 per share during the same quarter last year, which would indicate a negative year over year growth rate of 7.3%. The company is scheduled to issue its next quarterly earnings report on Thursday, February 14th.

On average, analysts expect that Medidata Solutions will report full-year earnings of $1.57 per share for the current fiscal year, with EPS estimates ranging from $1.50 to $1.72. For the next year, analysts forecast that the business will report earnings of $1.91 per share, with EPS estimates ranging from $1.71 to $2.10. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow Medidata Solutions.

Medidata Solutions (NASDAQ:MDSO) last issued its earnings results on Thursday, October 18th. The company reported $0.42 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.36 by $0.06. Medidata Solutions had a return on equity of 10.70% and a net margin of 8.43%. The business had revenue of $163.41 million during the quarter, compared to analysts’ expectations of $162.09 million. During the same period in the prior year, the business earned $0.33 EPS. The business’s revenue for the quarter was up 17.6% compared to the same quarter last year.

MDSO has been the subject of a number of analyst reports. ValuEngine cut Medidata Solutions from a “buy” rating to a “hold” rating in a research note on Monday, September 17th. Royal Bank of Canada decreased their price objective on Medidata Solutions to $91.00 and set an “outperform” rating for the company in a research note on Tuesday, September 25th. Morgan Stanley set a $84.00 price objective on Medidata Solutions and gave the stock a “hold” rating in a research note on Wednesday, July 25th. JPMorgan Chase & Co. cut Medidata Solutions from an “overweight” rating to a “neutral” rating and set a $87.00 price objective for the company. in a research note on Tuesday, July 24th. Finally, Piper Jaffray Companies reduced their target price on Medidata Solutions from $96.00 to $93.00 in a research report on Thursday. One investment analyst has rated the stock with a sell rating, five have given a hold rating and eight have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $85.25.

Shares of NASDAQ MDSO traded up $0.04 during mid-day trading on Monday, reaching $70.10. 3,033 shares of the company were exchanged, compared to its average volume of 832,482. The company has a debt-to-equity ratio of 0.15, a current ratio of 2.52 and a quick ratio of 1.41. The stock has a market capitalization of $4.18 billion, a P/E ratio of 82.35, a price-to-earnings-growth ratio of 4.34 and a beta of 1.44. Medidata Solutions has a 1 year low of $59.60 and a 1 year high of $88.87.

In related news, Director Robert Taylor sold 5,000 shares of the company’s stock in a transaction dated Tuesday, July 31st. The stock was sold at an average price of $73.05, for a total transaction of $365,250.00. Following the transaction, the director now directly owns 44,036 shares of the company’s stock, valued at approximately $3,216,829.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Michael I. Otner sold 9,288 shares of the company’s stock in a transaction dated Tuesday, July 24th. The shares were sold at an average price of $81.03, for a total value of $752,606.64. The disclosure for this sale can be found here. Insiders have sold a total of 26,788 shares of company stock worth $2,069,857 over the last ninety days. 4.70% of the stock is currently owned by corporate insiders.

A number of large investors have recently made changes to their positions in MDSO. World Asset Management Inc acquired a new position in shares of Medidata Solutions in the second quarter valued at about $235,000. Zeke Capital Advisors LLC acquired a new position in shares of Medidata Solutions in the second quarter valued at about $239,000. First Republic Investment Management Inc. acquired a new position in shares of Medidata Solutions in the second quarter valued at about $242,000. Zions Bancorporation acquired a new position in shares of Medidata Solutions in the second quarter valued at about $274,000. Finally, NJ State Employees Deferred Compensation Plan acquired a new position in shares of Medidata Solutions in the third quarter valued at about $293,000.

Medidata Solutions Company Profile

Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development of new therapies. The company's platform solutions include data capture and management and trial planning and management.

Featured Story: How can you know how many shares are floating?

Get a free copy of the Zacks research report on Medidata Solutions (MDSO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.